Previous close | 4.1900 |
Open | N/A |
Bid | 1.5500 |
Ask | 3.7000 |
Strike | 6.00 |
Expiry date | 2024-08-16 |
Day's range | 4.1900 - 4.1900 |
Contract range | N/A |
Volume | |
Open interest | 100 |
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.